scholarly journals High Expression of CTSV in Bladder Cancer as a Predictor of Poor Prognosis: A Study Based on TCGA and GEO Database

2021 ◽  
Author(s):  
Zhiqiang Yao ◽  
Jiajia Zhang ◽  
Chaohu Chen ◽  
Pan Li ◽  
Jinlong Cao ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Signaling Pathway ◽  
Poor Prognosis ◽  
Cox Regression ◽  
High Expression ◽  
Clinicopathologic Characteristics ◽  
Kaplan Meier ◽  
The Relationship ◽  
Low Expression ◽  
Geo Database

Abstract Background: Bladder cancer (BLCA) is the most common malignancy of urinary system with a high recurrence rate. We aimed to explore the relationship between cathepsin V (CTSV) expression and prognosis in patients with bladder cancer.Methods: The RNA-Seq gene expression data and corresponding clinical information with BLCA were downloaded from TCGA database. The gene expression profiles of GSE13507 and GSE133624 were downloaded from GEO database. BLCA patients were divided into high and low expression group according to the cutoff value of CTSV expression. The relationship between clinicopathologic characteristics and CTSV expression was analyzed with the Wilcoxon signed-rank test and logistic regression. Kaplan-Meier analysis and Cox regression were used to analyze the relationship between overall survival and clinicopathologic characteristics. Gene set enrichment analysis (GSEA) was utilized to identify enriched KEGG pathway.Results: High expression of CTSV was significantly correlated with pathological grade (OR = 1.662 for low vs. high), clinical stage (OR = 1.589 for I-II vs. III-IV), status (OR = 1.435 for normal vs. tumor), T stage (OR = 1.589 for T1-2 vs. T3-4), and M stage (OR = 4.499 for M0 vs M1). The expression of CTSV was significantly increased in BLCA compared with normal tissue (P < 0.001). Kaplan-Meier survival analysis showed that BLCA patients with high expression of CTSV had a poorer prognosis than low expression of CTSV patients (P = 0.0016). Univariate Cox analysis showed that high expression of CTSV was significantly associated with poorer overall survival (HR:1.662, 95%CI:1.209-2.286, P = 0.002). Multivariate Cox regression showed that high expression of CTSV was an independent risk factor for poor prognosis in BLCA patients (HR: 1.495, 95%CI: 1.069-2.089, P = 0.019). We also used the GSE13507 and GSE133624 to verify whether CTSV was differently expressed in bladder cancer tissues and normal tissues. The results showed that CTSV expression was significantly increased in BLCA patients (P < 0.05). Finally, GSEA was used to show 22 enriched signaling pathways in a high phenotype.Conclusion: High expression of CTSV in bladder cancer is associated with poor prognosis and may serve as a new biomarker. In addition, the chemokine signaling pathway, MAPK signaling pathway, Wnt signaling pathway, JAK-STAT signaling pathway, tight Junction and cell adhesion molecules may be the key pathway regulated by CTSV in BLCA.

High TRAF3IP3 Level Predicts Poor Prognosis of Patients with Gliomas

2020 ◽  
Author(s):  
Guorong Yang ◽  
Shu Tang ◽  
Jie Zhang ◽  
Ling Qin
Keyword(s):  
Signaling Pathway ◽  
Cox Regression ◽  
The Body ◽  
High Expression ◽  
Clinicopathological Parameters ◽  
Signal Pathways ◽  
Primary Therapy ◽  
Kaplan Meier ◽  
Wilcoxon Rank Sum Test ◽  
The Relationship

Abstract Purpose: TRAF3IP3 is involved in the maturation of immune cells, the development of immune tissues and the immune response of the body. TRAF3IP3 is shown to expressed in a variety of malignant tumor cell lines. Down-regulated expression of TRAF3IP3 in malignant melanoma can inhibit tumor growth. However, the role of TRAF3IP3 in glioma is still unknown. In this study, we aimed to study the relationship between TRAF3IP3 and glioma based on TCGA data.Method: We used the Wilcoxon rank sum test to compare the expression of TRAF3IP3 in glioma and normal tissues. Subsequently, Kruskal-Wallis test, Wilcoxon rank sum test, and logistics regression were used to evaluate the relationship between TRAF3IP3 and clinicopathological parameters of glioma patients. GSEA was used to verify the key signal pathways involved in TRAF3IP3. We used the ssGSEA method to analyze the relationship between the expression level of TRAF3IP3 and the immune infiltration in the glioma tumor microenvironment. Finally, we used Kaplan-Meier and COX regression to evaluate the prognostic value of TRAF3IP3.Results: TRAF3IP3 transcription level was highly expressed in gliomas(P<0.001). And the high expression of TRAF3IP3 and WHO grade(OR=3.57(2.42-5.34), P<0.001), IDH status (OR=4.79(3.40-6.83), P<0.001), 1P /19q codeletion (OR=0.07(0.04-0.11), P<0.001), EGFR status (OR=2.77(1.65-4.81), P<0.001), histological type (OR=3.64(2.48-5.43), P<0.001), age (OR=1.64(1.13-2.41), P=0.01), and primary therapy outcome (OR=2.29(1.47-3.61), P<0.001) were significantly correlated. GSEA showed that six signaling pathways were significantly enriched in the TRAF3IP3 high expression phenotype group, including JAK STAT signaling pathway, interferon-γ signaling pathway, apoptosis, P53 signaling pathway, PD-1 signaling pathway, and CTLA4 signaling pathway. ssGSEA showed that the expression of TRAF3IP3 was significantly positively correlated with the infiltration of Macrophages, Th17 cells, etc. Multivariate COX regression showed that TRAF3IP3 was an independent prognostic factor for glioma OS (HR=2.169(1.301-3.615), P=0.003). Kaplan-Meier analysis showed that high expression of TRAF3IP3 was associated with worse PFS(HR=2.39(1.39-3.01), P<0.001), DFS(HR=3.02(2.27-4.01), P<0.001) and OS(HR=2.87(2.20-3.75), P<0.001).Conclusion: TRAF3IP3 may play an important role in the occurrence and development of glioma, and may be a potential biomarker for the diagnosis and prognosis of glioma.

scholarly journals The relationship between CD204 M2-polarized tumour-associated macrophages (TAMs), tumour-infiltrating lymphocytes (TILs), and microglial activation in glioblastoma microenvironment: a novel immune checkpoint receptor target

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Maher Kurdi ◽  
Badrah Alghamdi ◽  
Nadeem Shafique Butt ◽  
Saleh Baeesa
Keyword(s):  
Microglial Activation ◽  
Inverse Correlation ◽  
Idh1 Mutation ◽  
High Expression ◽  
Kaplan Meier ◽  
Significant Difference ◽  
Tumour Infiltrating Lymphocytes ◽  
Infiltrating Lymphocytes ◽  
The Relationship ◽  
Low Expression

Abstract Background Tumour associated macrophages (TAMs) and tumour infiltrating lymphocytes (TILs) are considered dominant cells in glioblastoma microenvironment. Aim The purpose of this study was to assess the expression of CD204+ M2-polarized TAMs in glioblastomas and their relationship with CD4+TILs, Iba+microglia, and IDH1 mutation. We also exploreed the prognostic value of these markers on the recurrence-free interval (RFI). Methods The expressions of CD204+TAMs, CD4+TILs, and Iba1+microglia were quantitively assessed in 45 glioblastomas using immunohistochemistry. Kaplan–Meier analysis and Cox hazards were used to examine the relationship between these factors. Results CD204+TAMs were highly expressed in 32 tumours (71%) and the remaining 13 tumours (29%) had reduced expression. CD4+TILs were highly expressed in 10 cases (22%) and 35 cases (77.8%) had low expression. There was an inverse correlation between CD204+TAMs and CD4+TILs, in which 85% of tumours had a high expression of CD204+TAMs and a low expression of CD4+TILs. Nevertheless, there was no significant difference in IDH1 mutation status between the two groups (p = 0.779). There was a significant difference in Iba1+microglial activation between IDH1mutant and IDH1wildtype groups (p = 0.031). For cases with a high expression of CD204+TAMs and a low expression of CD4+TILs, there was a significant difference in RFI after treatment with chemoradiotherapy or radiotherapy (p = 0.030). Conclusion Glioblastoma with a dense CD204+TAMs and few CD4+TILs is associated with IDH1wildtype. These findings suggest that TAMs masks tumour cell and suppress T-cell tumoricidal functions via immunomodulatory mechanisms. Blockade of the CD204-TAM receptor may prevent this mechanism and allow the evolution of TILs.

Overexpression of C1QTNF6 Predicts a Poor Prognosis in Bladder Cancer

2020 ◽  
Author(s):  
Xin Zhu ◽  
Hang Tong ◽  
Shun Gao ◽  
Hubin Yin ◽  
Gongmin Zhu ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Poor Prognosis ◽  
Clinical Characteristics ◽  
Underlying Mechanism ◽  
High Expression ◽  
Migration And Invasion ◽  
Bladder Cell ◽  
Normal Bladder ◽  
Bladder Cancer Cells ◽  
Geo Database

Abstract Background: Bladder cancer is one of the most common urinary cancer. This study aimed to provide promising molecular biomarkers for bladder cancer by investigating the correlations between C1QTNF6 expressions and clinical characteristics as well as prognosis in patients with bladder cancer.Methods: C1QTNF6 RNA sequencing profiles of bladder cancer patients were collected to evaluate different expressions between normal bladder mucosa and bladder cancer from TCGA database and GEO database. The associations between C1QTNF6 expression and clinical characteristics as well as prognosis were evaluated by two independent cohorts. The cell expression of C1QTNF6 expression between normal bladder cell and bladder cancer cells were tested in western blot and PCR, and the underlying molecular mechanism was investigated.Results: RNA levels of C1QTNF6 were found to be differentially expressed in two independent public cohorts including TCGA database and GSE13507 from GEO database. The protein and RNA expressions C1QTNF6 in bladder cell lines were both significantly elevated than normal bladder cell line. High C1QTNF6 expressions were found in advanced T status, M status, pathological grade, AJCC stage compared with low C1QTNF6 expression group. The underlying mechanism may be explained by cell migration and invasion assays that bladder cancer cells 5637 and T24 were significantly reduced migration and invasion ability with the knock-down C1QTNF6 expressions. The low RNA expression group of C1QTNF6 demonstrated OS advantage over high-expression group in both TCGA and GSE13507 cohorts. Besides, protein expressions in tissues were further validated in HPA database and TMA. Survival analysis also indicated that the high expression of C1QTNF6 indicated unfavorable OS compared with low expressions group.Conclusions: High expression of C1QTNF6 predicted poor prognosis for bladder cancer patients, and the underlying mechanism is associated with cancer cell migration and invasion ability.

The Significance of Squamous Histology on Clinical Outcomes and PD-L1 Expression in Bladder Cancer

2021 ◽  
pp. 106689692110272
Author(s):  
Jennifer B. Gordetsky ◽  
Kathleen W. Montgomery ◽  
Giovanna A. Giannico ◽  
Soroush Rais-Bahrami ◽  
Prabin Thapa ◽  
...  
Keyword(s):  
Risk Factors ◽  
Bladder Cancer ◽  
Urothelial Carcinoma ◽  
Clinical Outcomes ◽  
Cox Regression ◽  
Squamous Differentiation ◽  
Clinicopathologic Characteristics ◽  
Cancer Specific Survival ◽  
Kaplan Meier ◽  
Never Smokers

Objectives. To compare the clinicopathologic characteristics of urothelial carcinoma (UC), urothelial carcinoma with squamous differentiation (UCSD), and squamous cell carcinoma (SCC) of the bladder, which have been suggested to differ in terms of risk factors, immunophenotype, and prognosis. Methods. We evaluated the clinicopathologic features of radical cystectomy specimens between 1980 and 2015 with a diagnosis of SCC, UCSD, and UC. PD-L1 immunohistochemistry (clinically available clones 22C3, SP142, and SP263) was performed on SCC and UCSD. Multivariate Cox regression was used to identify prognostic factors. Kaplan–Meier curves were plotted to assess cancer-specific survival (CSS). Results. Of the 1478 cases, there were 1126 UC (76%), 217 UCSD (15%), and 135 SCC (9%). Bladder cancer was more common in men than women (80% vs 20%, P < .0001). However, a higher proportion of SCC and UCSD occurred in women (SCC-36%, UCSD-22%, UC-18%). Women were significantly more likely to be never smokers in all 3 cohorts (UC: 45% vs 16%, UCSD: 44% vs 12%, SCC: 40% vs 18%, P < .0001). Patients with SCC and UCSD were at a higher pathologic stage (>pT2) at the time of cystectomy (UCSD-74%, SCC 71%, UC-44%, P < .0001) and had worse CSS compared to patients with UC ( P = 0.006). SCC had higher PD-L1 scores (all clones) than UCSD ( P < .0001). PD-L1 22C3 ( P = .02, HR: 0.36) and SP142 scores ( P = .046, HR: 0.27) predicted CSS on Kaplan–Meier analysis for SCC cases. Conclusions. UC, UCSD, and SCC are associated with different risk factors, gender distributions, and clinical outcomes. PD-L1 is expressed in SCC and UCSD, suggesting some patients may benefit from targeted therapy.

High expression of ISG20 predicts a poor prognosis in acute myeloid leukemia

2021 ◽  
pp. 1-7
Author(s):  
Hao Xiong ◽  
Xinwen Zhang ◽  
Xiaomin Chen ◽  
Yang Liu ◽  
Jialin Duan ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Poor Prognosis ◽  
Cox Regression ◽  
High Expression ◽  
Cox Regression Analysis ◽  
Kaplan Meier ◽  
Receive Treatment ◽  
To Receive ◽  
Acute Myeloid

BACKGROUND: Acute myeloid leukemia (AML) is one of the most malignant hematopoietic system diseases. Interferon stimulated exonuclease gene 20 (ISG20) is a protein induced by interferons or double-stranded RNA, which is associated with poor prognosis in several malignant tumors. However its expression in AML is unknown. OBJECTIVE: To explore the expression of ISG20 in AML and its prognostic significance. METHODS: The expression of ISG20 in AML patients was analyzed by GEPIA database, detected by qRT-PCR and their prognosis was followed-up. Chi-square test was used to identify the association between ISG20 expression and clinical characteristics of the patients. Kaplan-Meier analysis was performed to draw survival curves and Cox regression analysis to confirm the independent prognostic factors of AML patients. RESULTS: Kaplan-Meier analysis revealed that whether to receive treatment, Karyotype, and ISG20 expression were related to overall survival time of AML patients (P< 0.05). Cox regression analysis showed that whether to receive treatment (HR = 0.248, 95% CI = 0.076–0.808, P= 0.021) and high expression of ISG20 (HR = 4.266, 95% CI = 1.118–16.285, P= 0.034) were independent unfavorable prognostic factors for AML patients. CONCLUSION: The high expression of ISG20 acts as a poor prognosis indicator in AML patients.

scholarly journals High Expression of SRD5A3 in Human Hepatocellular Carcinoma (HCC) Predicts Poor Prognosis: A Study Based on TCGA Data

2021 ◽  
Author(s):  
Jing Xue ◽  
Xianzhao Yang ◽  
Feng Jiang
Keyword(s):  
Hepatocellular Carcinoma ◽  
Cell Cycle ◽  
Overall Survival ◽  
Poor Prognosis ◽  
Cox Regression ◽  
High Expression ◽  
Th2 Cells ◽  
Kaplan Meier ◽  
Potential Biomarker ◽  
Pathologic Features

Abstract Background: Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related death worldwide. Steroid 5 alpha-reductase 3 (SRD5A3) was reported to be up-regulated in many types of cancer. However, its expression and role in HCC remains to be elucidated. We aim to evaluate the significance of SRD5A3 expression in HCC by using analysis of a public dataset from The Cancer Genome Atlas (TCGA).Methods: The relationship between clinical pathologic features and SRD5A3 were analyzed with the Kolmogorov‐Smirnov test and the logistic regression. Cox regression and the Kaplan-Meier method were used to assess the clinicopathologic characteristics associated with overall survival (OS) in TCGA patients. In addition, GSEA was used to predict potential hallmarks associated with different expression of SRD5A3 on transcriptional sequences from TCGA database.Results: SRD5A3 was highly expressed in HCC tumor tissue compared to normal tissue. A total of 184 upregulated DEGs (differentially expressed genes) and 58 downregulated DEGs were identified between high expression and low expression of SRD5A3. Among them, 22 hub genes mainly belonging to the keratin and MUC family demonstrated by connectivity degree in the PPI network were screened out. Kaplan-Meier method showed that HCC patients in the high SRD5A3 expression group had poorer overall survival (OS, HR=2.26(1.58-3.24), p<0.001). In addition, cell cycle mitotic, cell cycle checkpoints, mitotic nuclear division, Q-glycan processing, protein O-linked glycosylation were differentially enriched in the high SRD5A3 expression phenotype pathway. In addition, SRD5A3 expression level has significant correlations with infiltrating levels of Th17 (R = -0.238, p < 0.001), Cytotoxic cells (R = -0.234, p < 0.001) and Th2 cells (R = 0.258, p < 0.001) in HCC.Conclusions: High expression of SRD5A3 was significantly correlated with poor prognosis in HCC patients. It may be a potential biomarker in HCC.

scholarly journals Overexpression of MAL2 Correlates with Immune Infiltration and Poor Prognosis in Breast Cancer

2021 ◽  
Vol 2021 ◽  
pp. 1-15
Author(s):  
Yue Zhong ◽  
Zhenjie Zhuang ◽  
PeiJu Mo ◽  
Qi Shang ◽  
Mandi Lin ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Dendritic Cells ◽  
Poor Prognosis ◽  
Cox Regression ◽  
Plasmacytoid Dendritic Cells ◽  
Chi Square ◽  
Exact Test ◽  
Kaplan Meier ◽  
Chi Square Test ◽  
The Relationship

Background. Myelin and lymphocyte, T cell differentiation protein 2 (MAL2) is highly expressed in various cancers and associated with the development and prognosis of cancer. However, the relationship between MAL2 and breast cancer requires further investigation. This study aimed to explore the prognostic significance of MAL2 in breast cancer. Methods. MAL2 expression was initially assessed using the Oncomine database and The Cancer Genome Atlas (TCGA) database and verified by quantitative real-time polymerase chain reaction (RT-qPCR). The chi-square test or Fisher’s exact test was used to explore the association between clinical characteristics and MAL2 expression. The prognostic value of MAL2 in breast cancer was assessed by the Kaplan–Meier method and Cox regression analysis. Gene set enrichment analysis (GSEA) was performed to identify the biological pathways correlated with MAL2 expression in breast cancer. Besides, a single-sample GSEA (ssGSEA) was used to assess the relationship between the level of immune infiltration and MAL2 in breast cancer. Results. Both bioinformatics and RT-qPCR results showed that MAL2 was expressed at high levels in breast cancer tissues compared with the adjacent tissues. The chi-square test or Fisher’s exact test indicated that MAL2 expression was related to stage, M classification, and vital status. Kaplan–Meier curves implicated that high MAL2 expression was significantly associated with the poor prognosis. Cox regression models showed that high MAL2 expression could be an independent risk factor for breast cancer. GSEA showed that 14 signaling pathways were enriched in the high-MAL2-expression group. Besides, the MAL2 expression level negatively correlated with infiltrating levels of eosinophils and plasmacytoid dendritic cells in breast cancer. Conclusion. Overexpression of MAL2 correlates with poor prognosis and lower immune infiltrating levels of eosinophils and plasmacytoid dendritic cells in breast cancer and may become a biomarker for breast cancer prognosis.

scholarly journals Upregulation of FGD6 Predicts Poor Prognosis in Gastric Cancer

2021 ◽  
Vol 8 ◽  
Author(s):  
Jianmin Zeng ◽  
Man Li ◽  
Huasheng Shi ◽  
Jianhui Guo
Keyword(s):  
Gastric Cancer ◽  
Regression Analysis ◽  
Prognostic Factor ◽  
Poor Prognosis ◽  
Cox Regression ◽  
Independent Prognostic Factor ◽  
Gene Set Enrichment Analysis ◽  
High Expression ◽  
Cox Regression Analysis ◽  
The Relationship

Background: The aim of this study was to investigate the prognostic significance of faciogenital dysplasia 6 (FGD6) in gastric cancer (GC).Methods: The data of GC patients from The Cancer Genome Atlas (TCGA) database were used for the primary study. Then, our data were validated by the GEO database and RuiJin cohort. The relationship between the FGD6 level and various clinicopathological features was analyzed by logistic regression and univariate Cox regression. Multivariate Cox regression analysis was used to evaluate whether FGD6 was an independent prognostic factor for survival of patients with GC. The relationship between FGD6 and overall survival time was explored by the Kaplan–Meier method. In addition, gene set enrichment analysis (GSEA) was performed to investigate the possible biological processes of FGD6.Results: The FGD6 level was significantly overexpressed in GC tissues, compared with adjacent normal tissues. The high expression of FGD6 was related to a high histological grade, stage, and T classification and poor prognosis of GC. Multivariate Cox regression analysis showed that FGD6 was an independent prognostic factor for survival of patients with GC. GSEA identified that the high expression of FGD6 was mainly enriched in regulation of actin cytoskeleton.Conclusion: FGD6 may be a prognostic biomarker for predicting the outcome of patients with GC.

scholarly journals OLFML2B Is a Robust Prognostic Biomarker in Bladder Cancer Through Genome-Wide Screening: A Study Based on Seven Cohorts

2021 ◽  
Vol 11 ◽  
Author(s):  
Jiaxing Lin ◽  
Xiao Xu ◽  
Tianren Li ◽  
Jihang Yao ◽  
Meng Yu ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Prognostic Marker ◽  
Poor Prognosis ◽  
Immune Cell ◽  
High Expression ◽  
Tumor Associated Macrophage ◽  
Kaplan Meier ◽  
Genome Wide ◽  
Patients At Risk ◽  
High Level

BackgroundBladder cancer lacks useful and robust prognostic markers to stratify patients at risk. Our study is to identify a robust prognostic marker for bladder cancer.MethodsThe transcriptome and clinical data of bladder cancer were downloaded from multiple databases. We searched for genes with robust prognosis by Kaplan-Meier analysis of the whole genome. CIBERSORT and TIMER algorithm was used to calculate the degree of immune cell infiltration.ResultsWe identified OLFML2B as a robust prognostic marker for bladder cancer in five cohorts. Kaplan-Meier analysis showed that patients with a high level of OLFML2B expression had a poor prognosis. The expression of OLFML2B increased with the increase of stage and grade. We found that patients with high expression of OLFML2B still had a poor prognosis in two small bladder cancer cohorts. OLFML2B also has the prognostic ability in ten other tumors, and the prognosis is poor in high expression. The correlation analysis between OLFML2B and immune cells showed that it was positively correlated with the degree of macrophage infiltration and highly co-expressed with tumor-associated macrophage markers. Finally, the Wound-healing assay and Colony formation assay results showed that the migration and proliferation ability of bladder cancer cell lines decreased after the knockdown of OLFML2B.ConclusionsIn summary, OLFML2B is a robust risk prognostic marker, and it can help patients with bladder cancer improve individualized treatment.

scholarly journals Expression and clinical significance of CMTM1 in hepatocellular carcinoma

Open Medicine ◽  
2021 ◽  
Vol 16 (1) ◽  
pp. 217-223
Author(s):  
Xin Song ◽  
Shidong Zhang ◽  
Run Tian ◽  
Chuanjun Zheng ◽  
Yuge Xu ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Transmembrane Domain ◽  
Disease Free Survival ◽  
Clinicopathological Characteristics ◽  
The Cancer Genome Atlas ◽  
High Expression ◽  
Chi Square ◽  
Tumor Tissues ◽  
The Relationship ◽  
Low Expression

Abstract Background CKLF Like Marvel Transmembrane Domain Containing 1 (CMTM1) plays a role in breast cancer and lung cancer, but studies on the occurrence and development of CMTM1 in hepatocellular carcinoma (HCC) have not been reported. Methods The Cancer Genome Atlas (TCGA) database and immunohistochemistry (IHC) were used to detect CMTM1 expression in HCC tissues. The relationship between CMTM1 expression and the clinicopathological characteristics of HCC patients was analyzed by chi-square test, and the relationship between CMTM1 expression and the prognosis of HCC patients was tested by the Kaplan–Meier model. Results Bioinformatics analysis showed that the mRNA expression of CMTM1 was upregulated in HCC tissues, and low expression of CMTM1 is associated with longer disease-free survival in patients with HCC. Similarly, the survival time of HCC patients in CMTM1 high expression group was significantly shorter than that in CMTM1 low expression group. IHC detection indicated that CMTM1 protein was highly expressed in both HCC and adjacent non-tumor tissues, with a positive expression in 84% (63/75) of HCC tissues and 89.3% (67/75) of adjacent non-tumor tissues. Moreover, CMTM1 expression was related to family history and TNM stage of HCC patients (P < 0.05), but had no relationship with other clinicopathological characteristics. The survival analysis based on IHC results showed that the prognosis of HCC patients in CMTM1 negative group was significantly poorer than that in CMTM1 positive group (P < 0.05). Conclusion CMTM1 has a high expression in HCC tissues and is related to the prognosis of HCC patients.

Sign in / Sign up

Export Citation Format

Share Document